Nuvectis Pharma (NVCT) Return on Capital Employed (2022 - 2026)
Nuvectis Pharma (NVCT) posted Return on Capital Employed of 162.68% for Q1 2026, down 20.07% sequentially from 135.49% in Q4 2025, and down 2424.0% YoY from 7.0% in Q1 2025.
Nuvectis Pharma (NVCT) Return on Capital Employed (2022 - 2026) Analysis & Trends
Nuvectis Pharma has reported Return on Capital Employed for 5 years, with the latest figure at 162.68% in Q1 2026.
- Quarterly Return on Capital Employed fell 2424.0% year-over-year to 162.68% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 162.68% (down 2424.0% YoY) and the FY2025 annual result came in at 232.46%, down 3403.0% from the prior year.
- Return on Capital Employed declined to 162.68% in Q1 2026 per NVCT's latest filing, from 135.49% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 97.75% in Q3 2022 and troughed at 218.99% in Q4 2024.
- A 5-year average of 146.66% and a median of 141.49% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 5234 bps in 2024, then jumped 8350 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 116.93% in 2022, then sank by 43 bps to 166.65% in 2023, then plunged by 31 bps to 218.99% in 2024, then surged by 38 bps to 135.49% in 2025, then dropped by 20 bps to 162.68% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 162.68%, 135.49%, and 133.9% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | -272.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -272.52% |
| Mar 31, 2026 | -162.68% |
| Dec 31, 2025 | -135.49% |
| Sep 30, 2025 | -133.90% |
| Jun 30, 2025 | -124.55% |
| Mar 31, 2025 | -138.43% |
| Dec 31, 2024 | -218.99% |
| Sep 30, 2024 | -176.42% |
| Jun 30, 2024 | -166.69% |
| Mar 31, 2024 | -168.58% |
| Dec 31, 2023 | -166.65% |
| Sep 30, 2023 | -126.54% |
| Jun 30, 2023 | -141.49% |
| Mar 31, 2023 | -141.87% |
| Dec 31, 2022 | -116.93% |
| Sep 30, 2022 | -97.75% |
| Jun 30, 2022 | -101.98% |
| Mar 31, 2022 | -174.21% |